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OBJECTIVE — To study the association between impaired glucose regulation (IGR), screen-
detected type 2 diabetes, and previously known diabetes and depressive symptoms.
RESEARCH DESIGN AND METHODS — Altogether, 2,712 participants from three
hospital districts in Finland attended a health examination. Cutoff scores 10 and 16 in the
21-item Beck Depression Inventory (BDI-21) were used for depressive symptoms. The partici-
pantsweredeﬁnedashavingknowndiabetesiftheyreporteddiabetes.Anoralglucosetolerance
test was used to detect normal glucose regulation (NGR), impaired fasting glucose (IFG), im-
paired glucose tolerance (IGT), and screen-detected diabetes. The participants were deﬁned as
having IGR if they had IFG or IGT.
RESULTS — Prevalence of depressive symptoms, deﬁned as a BDI-21 cutoff score 10, was
14.4% for those with NGR, 13.7% for those with IGR, 14.8% for those with screen-detected
diabetes, and 26.4% for those with previously known diabetes. The corresponding prevalences
for a cutoff score 16 were 3.4, 3.4, 4.2, and 7.5%, respectively. Compared with NGR and
adjusted for demographic, lifestyle, and biological factors, the odds ratios for IGR, screen-
detected diabetes, and previously known diabetes were 0.91 (95% CI 0.69–1.20), 0.70 (0.45–
1.08), and 1.35 (0.84–2.15), respectively, for a cutoff score 10. For a cutoff score 16, the
corresponding odds ratios were 1.05 (0.62–1.76), 0.87 (0.40–1.90), and 1.56 (0.69–3.50),
respectively.
CONCLUSIONS — Participantswithdiagnoseddiabeteshadahigherprevalenceofdepres-
sive symptoms than participants with NGR, IGR, and previously unknown diabetes. When
potential confounding factors were included in the analysis, previously known diabetes was not
signiﬁcantly associated with depressive symptoms.
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t is widely recognized that depression
is more common among people with
diabetesthaninthegeneralpopulation
(1). However, previous studies (2–10)
that have assessed the relationship be-
tween depressive symptoms and im-
pairedglucosetolerance(IGT)ordiabetes
have been inconsistent. A German study
(4) that included 4,597 subjects and a
Dutch study (2) that included 4,747 par-
ticipants found no association between
type2diabetesanddepressivesymptoms.
In a general-practice setting study that in-
cluded 2,849 male and 3,160 female sub-
jects, depression was not more prevalent
in people with screen-detected diabetes
orimpairedglucoseregulation(IGR)than
in people with normal glucose regulation
(NGR) (5). Contrary to these studies,
withintheHertfordshireCohortStudy(6)
there was a relationship between depres-
sion scores and diagnosed and previously
undiagnosed diabetes. A U.S. study (8)
including 4,293 U.S. veterans indicated
that men with undiagnosed type 2 diabe-
tes had nearly double the odds of major
depression compared with those with
normal fasting glucose.
In 1992, it was stated about the rela-
tionshipbetweendepressionanddiabetes
that“theetiologyisunknownbutisprob-
ablycomplex;andbiological,genetic,and
psychological factors remain as potential
contributors.Severalneuroendocrineand
neurotransmitter abnormalities common
to both depression and diabetes have
been identiﬁed, adding to etiological
speculations” (11). It has been suggested
that stress-induced activation of the hy-
pothalamic-pituitary-adrenalaxismayre-
sult in the development of metabolic
abnormalities and depression (12). In ad-
dition, possible neuroendocrine abnor-
malitiesassociatedwithbothdiabetesand
depressivesymptomsmayincludeabnor-
malities in vitamin B12 and sex hormone–
binding globulin (SHBG) levels. Low
vitamin B12 levels have been found to re-
latetotype2diabetes(13)anddepressive
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may predict diabetes (17). SHBG binds
circulating sex hormones, which have
been suggested to be associated with de-
pressive symptoms (18). In addition to
these biological factors, the observed as-
sociation between diabetes and depres-
sivesymptomscouldbeareﬂectionofthe
burden of diabetes and comorbidities.
In the present study, our aim was to
analyze the prevalence of depressive
symptoms in people with NGR, IGR (in-
cluding impaired fasting glycemia and
impaired glucose tolerance), screen-
detected (previously unknown) diabetes,
and previously known type 2 diabetes.
Furthermore, our aim was to study the
association between glucose tolerance
and depressive symptoms, taking into ac-
count potential confounding demo-
graphic and biological factors as well as
comorbidity.
RESEARCH DESIGN AND
METHODS— The Finnish Type 2 Di-
abetes (FIN-D2D) Population Survey was
conducted in the hospital districts of Pir-
kanmaa, southern Ostrobothnia, and
central Finland between October and De-
cember 2007. A random sample of 4,500
people, aged 45–74 years, stratiﬁed ac-
cording to sex, 10-year age-groups (45–
54, 55–64, and 65–74 years), and
geographical areas, was selected from the
National Population Register in August
2007.Thestudyparticipantswereinvited
by mail to a health examination. A total of
2,868 subjects (64%) participated in the
health examination. Information on glu-
cose tolerance status was available from
2,712 participants. All the participants
signed an informed consent form. Ethical
permission for the study was granted by
the ethics committee of the Hospital Dis-
trict of Helsinki and Uusimaa.
Theparticipantsattendedahealthex-
amination conducted by a trained nurse
in accordance with the multinational
Monitoring of Trends and Determinants
in Cardiovascular Disease (MONICA)
protocol (19). Fasting venous blood sam-
ples were drawn into a gel serum tube
(Venosafe; Terumo Europe, Leuven, Bel-
gium) that contained a clot activator for
insulin, vitamin B12, SHBG, tireotrophin-
stimulating hormone (TSH), and high-
sensitivity C-reactive protein (hs-CRP)
andintoaﬂuoride-citratetube(Venosafe)
for fasting plasma glucose (FPG). The se-
rumandﬂuoride-citrateplasmaweresep-
arated within1hb ycentrifuging at
2,200g for 11 min at room temperature.
After which the serum and plasma were
aliquoted into storage tubes (Nalgene;
Thermo Fisher Scientiﬁc, Rochester, NY)
and stored locally at a minimum of
20°Candthentransportedfrozentothe
NationalInstituteforHealthandWelfare,
where all the samples were stored at 70
C° until analyzed. All the samples were
analyzedinthesamelaboratoryattheNa-
tionalInstituteforHealthandWelfareus-
ing an Architect ci8200 analyzer (Abbott
Laboratories, Abbott Park, IL) for insulin,
vitaminB12,SHBG,hs-CRP,andFPGand
an Axsym analyzer (Abbott) for TSH. The
following methods were used: the chemi-
luminescent microparticle immuno
method(Abbott)formeasuringserumin-
sulin, vitamin B12, and SHBG; the micro-
particle enzyme immuno method (third
generation; Abbott) for measuring serum
TSH; the latex immunoturbidimetric
method (Sentinel Diagnostics, Milan, It-
aly)formeasuringserumhs-CRP;andthe
enzymatic hexokinase method for plasma
glucose. To standardize its measure-
ments, the laboratory has taken part in
External Quality Assessment Schemes or-
ganized by Labquality (Helsinki, Fin-
land). During the course of the study, the
coefﬁcient of variation of the different
control levels (n  3) between days
(means  SD) for insulin, vitamin B12,
SHBG, TSH, hs-CRP, and FPG measure-
ments were 2.3  0.5%, 6.7  2.1%,
4.8  0.2%, 5.0  1.2%, 2.9  0.8%,
and 1.1  0.1%, respectively. A 2-h 75-g
standard oral glucose tolerance test
(OGTT) was conducted. Height (in cm)
and weight (in kg) were measured with
lightclothingandwithoutshoes.BMIwas
calculated as weight in kilograms divided
by the square of height in meters.
We deﬁned impaired glucose toler-
ance (IGT) (FPG level 7.0 mmol/l and a
2-h glucose value of 7.8–11.0 mmol/l)
and impaired fasting glucose (IFG) (FPG
6.1–6.9 mmol/l and a 2-h glucose value
7.8 mmol/l). IFG and IGT were
grouped together as IGR. Participants
were deﬁned as having screen-detected
type 2 diabetes if they had not previously
been diagnosed with diabetes and their
FPG was 7.0 mmol/l or 2-h glucose
11.1 mmol/l at the health examination.
Participantsweredeﬁnedashavingprevi-
ously known type 2 diabetes if they re-
ported a history of diabetes. The
participants were deﬁned as having NGR
if they had not been diagnosed with dia-
betes and if their FPG was 6.1 mmol/l
and 2-h glucose 7.8 mmol/l. Accord-
ingly, the glucose regulation categories
wereNGR,IGR,screen-detecteddiabetes,
and previously known diabetes.
Depressive symptoms were assessed
usingthe21-itemBeckDepressionInven-
tory (BDI-21) (20). The items in the
BDI-21 are summed into a total score (0–
63), with higher scores indicating more
severe depressive symptoms. The applied
cutoff score for depressive symptoms was
10.In addition, we used a cutoff score
of 16 to increase speciﬁcity for de-
pression (21). Current use of antide-
pressive medication was asked in the
questionnaire.
The participants reported their lei-
sure-time physical activity (LTPA) into
three categories: 1) low: almost com-
pletely inactive (e.g., reading, watching
television, or doing some minor physical
activity); 2) moderate: some physical ac-
tivitymorethan4haweek(e.g.,walking,
cycling, light gardening, ﬁshing, or hunt-
ing); and 3) high: vigorous physical activ-
i t ym o r et h a n3haweek or regular
exercise or competitive sports several
times a week (e.g., running, jogging, ski-
ing, swimming, ball games, or heavy gar-
dening). Current smoking was assessed
and dichotomized (no or yes). Education
was assessed according to years of educa-
tion. Marital status was asked, and mar-
riage or common-law marriage were
combined as cohabiting and single, di-
vorced, or widowed were combined as
living alone.
The participants were asked about
chronic diseases and disorders diagnosed
by a physician. Chronic pulmonary dis-
eases included asthma and chronic ob-
structive pulmonary disease. Heart
diseases included ischemic heart disease
and chronic heart failure. Chronic mus-
culoskeletal disorder included arthritis
and other chronic joint disorders and
chronic back disease. In addition, the
presence of any cancer was asked.
The descriptive statistics are pre-
sentedwithmeansormediansandSDsor
interquartile range (IQR) for continuous
variables. Numbers and percentages are
presented for categorical variables. The
crudeprevalenceofdepressivesymptoms
was calculated, and CIs for the percent-
ages were obtained by exact (Clopper-
Pearson) methods. The relationship
between glucose tolerance status and de-
pressive symptoms was estimated using
multivariate logistic regression analysis.
In addition to age, sex, physical activity,
BMI,education,andmaritalstatus,wein-
cluded hs-CRP, TSH, SHBH, vitamin B12,
and the comorbidity sum (including
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heart diseases, and cancer) in the multi-
variate analysis as potential factors inter-
fering with the relationship between
glucose tolerance status and depressive
symptoms. Stata statistical software, re-
lease 11.0 (StataCorp, College Station,
TX), was used for the analyses.
RESULTS— Of all the participants,
1,268 had NGR (47%), 1,001 had IGR
(37%), 284 had screen-detected diabetes
(10%), and 159 had previously known
diabetes (6%). The descriptive character-
isticsofthestudypopulationaccordingto
thesegroupsarepresentedinTable1.The
proportion of female subjects was highest
in the NGR group. The people with
screen-detected diabetes and previously
known diabetes were older than those
with NGR or IGR. In the people with pre-
viously known diabetes, BMI, hs-CRP,
FPG,andfastinginsulinwerehighest,but
SHBGandvitaminB12werelowest.Alow
levelofLTPAanduseofanantidepressant
were most common among the people
with diabetes. Smoking was least preva-
lent among the people with screen-
detected and previously known diabetes.
Compared with the people with NGR or
IGR, the prevalence of chronic pulmo-
nary disease was twofold and the preva-
lence of heart disease was fourfold among
the people with previously known
diabetes.
The median (IQR) BDI-21 scores
were 4 (1–7), 3 (1–7), 4 (1–8), and 6
(3–10) for the people with NGR, IGR,
screen-detected, and previously known
diabetes, respectively. The crude preva-
lence of depressive symptoms with a cut-
off score 10 was higher among the
people with previously known diabetes
(n  42) (26.4% [95% CI 19.7–34.0])
than among the people with NGR (n 
183) (14.4% [12.5–16.5%]), IGR (n 
137) (13.7% [11.6–16.0]), and screen-
detecteddiabetes(n42)(14.8%[10.9–
19.5]) (P  0.001, previously known
diabetes vs. other groups). These preva-
lences were similar among the people
with NGR, IGR, and screen-detected dia-
betes (P  0.84). When a cutoff score of
16 was used, the corresponding preva-
lencewas3.4%forNGR(n43)(95%CI
2.5–5.4.5), 3.4% for IGR (n  34) (95%
CI 2.3–4.7), 4.2% for screen-detected di-
abetes (n  12) (95% CI 2.2–7.3), and
7.5% for previously known diabetes (n 
12) (95% CI 4.0–12.8) (P  0.009, pre-
viouslyknowndiabetesvs.othergroups).
These prevalences were similar among
the people with NGR, IGR, and screen-
detected diabetes (P  0.77).
In the multivariate logistic regression
analysisadjustedwithsosiodemographic,
lifestyle, and biological factors as well as
comorbidity, with a cutoff score 10 for
depressive symptoms, IGR, screen-
detected diabetes, and previously known
diabetes were not signiﬁcantly associated
with depressive symptoms when com-
pared with NGR (Table 2). The ﬁndings
were quite similar for both cutoff scores.
However, when a BDI-21 cutoff score
16 was used, the odds ratio for diabetes
was higher but the CIs were broader.
LTPA, living alone, comorbidity, and de-
pressive medication were associated with
depressive symptoms for both cutoff
scores,butfemalesexwasassociatedwith
depressive symptoms only when a cutoff
score 10 was used.
CONCLUSIONS — Thepresentpop-
ulation-based study indicates that people
with previously known type 2 diabetes
have depressive symptoms more com-
monly than people with IGR or NGR or
previously unknown (screen-detected)
type2diabetes.However,whenotherpo-
tentialconfoundingfactorswereincluded
in the analysis, previously known diabe-
tes was not signiﬁcantly associated with
depressivesymptoms.Ofthesefactors,fe-
male sex (not for a BDI-21 cutoff score
16),physicalinactivity,livingalone,co-
morbidities, and antidepressive medica-
tion were associated with depressive
symptoms. Vitamin B12, TSH, or SHBG
were not associated with depressive
symptoms, although vitamin B12 and
SHBG levels were lower among the peo-
plewithknowndiabetes.Thecrudeprev-
alenceofdepressivesymptomsamongthe
participantswithpreviouslyunknowndi-
abetes was similar to that in the partici-
pants with normal or impaired glucose
regulation.
Our results are in line with previous
studies suggesting that depression is not
more prevalent among people with
screen-detected diabetes or IGR (2,4,22)
and that there is no association between
depressive symptoms and unrecognized
glucoseintolerance(3).Findingsfromthe
Table 1—Characteristics of the study population according to glucose regulation status
NGR IGR
Screen-
detected type 2
diabetes
Previously
known type 2
diabetes
n 1,268 1,001 284 159
Female (%) 795 (63) 443 (44) 118 (42) 67 (42)
Age (years) 58  86 0  86 2  86 4  7
BMI (kg/m
2) 26.1  4.2 27.9  4.5 29.9  4.9 31.8  6.2
FPG (mmol/l) 5.7  0.82 6.3  0.38 7.3  1.5 8.4  2.1
Serum insulin (mU/l) 5.4 (4.1–7.2) 7.3 (5.4–10.1) 9.9 (6.9–14.2) 11.9 (7.2–16.9)
Hs-CRP (mg/l) 2.1  4.3 3.1  8.5 3.6  7.7 3.4  10.9
Serum vitamin B12
(pmol/l) 333  123 329  202 324  116 266  136
SHBG (nmol/l) 66.5  31.6 56.3  27.3 53.0  27.3 48.0  28.8
Serum TSH (mU/l) 3.26  2.37 2.99  1.67 3.10  1.91 3.32  2.77
LTPA
Low 206 (16) 179 (18) 75 (26) 51 (32)
Moderate 737 (58) 597 (60) 172 (61) 90 (57)
High 325 (26) 225 (22) 37 (13) 18 (11)
Marriage or common-law
marriage 966 (77) 783 (79) 203 (71) 119 (75)
Education in years 11 (9–15) 10 (8–13) 10 (8–12) 10 (8–12)
Current smoking 289 (23) 226 (23) 54 (19) 28 (18)
Antidepressive medication 64 (5) 53 (5) 23 (8) 11 (7)
Chronic pulmonary
disease 95 (8) 70 (7) 30 (11) 29 (18)
Chronic heart disease 82 (6) 98 (10) 38 (13) 39 (25)
Chronic musculoskeletal
disorder 371 (30) 306 (31) 96 (35) 64 (41)
Cancer 29 (2) 27 (3) 10 (4) 6 (4)
Data are means  SD, median (IQR), n,o rn (%).
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ple with low and very high glucose levels
had elevated depression scores, but low
depression scores were observed in both
normal and prediabetic ranges of fasting
glucose.Acontradictoryﬁndingwaspub-
lished recently (8). That study suggested
that a U-shaped association between fast-
ingglucoseanddepressiondoesnotexist.
Further, the study found that people ful-
ﬁlling type 2 diabetes criteria were more
depressedthanhealthypeople,regardless
of awareness of the disease. OGTT was
not used in that study, and it included
only men who were younger (mean age
39 years) than the participants in our
study. In addition, that study population
was exposed to long-lasting stressful cir-
cumstances in the Vietnam War, which
may have had an inﬂuence on the occur-
rence of diabetes and depression.
Compared with low physical activity,
moderate and especially high physical ac-
tivity were inversely related to depressive
symptoms. Previously, a systematic re-
view (23) has reported an inverse associ-
ation between physical activity and the
likelihood of depressive symptoms. The
associationbetweensmokinganddepres-
sive symptoms did not reach statistical
signiﬁcance, which is line with a previous
population-basedstudy(4).Inthatstudy,
living alone was related to depressive
symptoms,whichwasclearlyindicatedin
the present study as well. These ﬁndings
suggest that at least part of the increased
level of depressive symptoms among the
people with diabetes is explained by life-
style factors and marital status. Antide-
pressive medication was strongly
associated with depressive symptoms, es-
pecially when a higher BDI-21 cutoff
score was used. Antidepressive medica-
tion can be regarded as an indicator of
depressive people, but this ﬁnding may
also reﬂect suboptimal treatment of
depression.
The present study was based on a
population-based sample, and fasting
plasmaglucosewasincludedincategoriz-
ing the participants. As expected, screen-
detected diabetes fasting plasma levels
were elevated in people with IGR and
more elevated in people with screen-
detected diabetes. Fasting plasma glucose
levels were highest among people with
previously known diabetes, which indi-
cates suboptimal hyperglycemic control.
A meta-analytic review (24) has shown
that depression is associated with hyper-
glycemia in patients with diabetes. A re-
cent study (25) provided support for the
view that high diabetes-related distress
and clinical depression are related to dis-
ease management variables, but only dia-
betes-related distress is positively linked
to A1C and inversely to physical activity.
In addition to sociodemographic factors,
smoking, physical activity, and comor-
bidities, we included several potential bi-
ological confounding variables in our
analysis. In this analysis vitamin B12,
TSH, and SHBG did not play a role in the
relationship between depressive symp-
toms and glucose regulation.
Recent population-based studies
(2,4) have indicated that there was no
clear association between diabetes and
depressive symptoms. In line with those
studies, the present study indicated that
comorbidities were signiﬁcantly associ-
ated with depressive symptoms. The data
of the present study showed that people
with diabetes very often have other so-
matic diseases. Having a somatic comor-
bidity seemed to be strongly associated
withdepressivesymptoms.Therefore,the
ﬁndings of the present study support the
view that an increased prevalence of de-
pressive symptoms among people with
diabetes is related by their excessive dis-
ease burden. However, the current study
cannot rule out the possibility that com-
mon underlying physiological factors
play a role.
Depressive symptoms were deﬁned
on the basis of self-reported data. A diag-
nostic interview was not undertaken,
which can be regarded as a limitation of
our study. However, a BDI with a cutoff
score of 10 points has been shown to be a
feasibleinstrumentfordepressionscreen-
ing (20), and a cutoff score of 16 points
has been shown to be feasible for detect-
ing depression among outpatients with
diabetes (21). The present study was
based on cross-sectional data, and, there-
fore, we are not able to draw any conclu-
sions about causality. Further, we are not
able to exclude the possibility that dura-
tion of disease is related to the present
ﬁndings. The strength of this study is the
large representative population sample of
middle-aged men and women. Contrary
Table 2—Multivariate logistic regression analysis with depressive symptoms (BDI-21 >10
and BDI-21 >16) as an outcome
BDI-21 10 BDI-21 16
Odds ratio
(95% CI) P
Odds ratio
(95% CI) P
Glucose regulation
NGR 1.00 (Reference) 1.00 (Reference)
IGR 0.91 (0.69–1.20) 0.50 1.05 (0.62–1.76) 0.86
Screen-detected type 2
diabetes 0.70 (0.45–1.08) 0.10 0.87 (0.40–1.90) 0.73
Previously known type 2
diabetes 1.35 (0.84–2.15) 0.22 1.56 (0.69–3.50) 0.28
Female 0.69 (0.53–0.89) 0.004 0.82 (0.51–1.33) 0.43
Age (years) 0.056* 0.077*
45–54 1. 00 (Reference) 1.00 (Reference)
55–64 0.86 (0.63–1.19) 0.58 (0.33–1.02)
65–74 1.37 (0.98–1.91) 0.56 (0.30–1.06)
BMI 1.00 (0.98–1.03) 0.86 1.02 (0.98–1.07) 0.29
hs-CRP 1.00 (0.99–1.02) 0.61 0.99 (0.96–1.03) 0.68
Vitamin B12 1.00 (1.00–1.00) 0.19 1.00 (1.00–1.00) 0.28
SHBG 1.00 (1.00–1.00) 0.82 1.00 (0.99–1.01) 0.98
LTPA 0.001* 0.002*
Low 1.00 (Reference) 1.00 (Reference)
Moderate 0.47 (0.35–0.62) 0.43 (0.27–0.69)
High 0.29 (0.19–0.43) 0.28 (0.13–0.60)
Marriage or common-law
marriage 0.67 (0.51–0.87) 0.003 0.49 (0.31–0.78) 0.002
Education (per year) 0.97 (0.94–1.01) 0.14 0.98 (0.92–1.04) 0.50
Smoking 1.27 (0.95–1.69) 0.11 1.42 (0.86–2.33) 0.17
Comorbidity sum 1.71 (1.46–2.01)  0.001 1.59 (1.19–2.12) 0.002
Antidepressive medication 6.28 (4.33–9.12) 0.001 9.57 (5.87–15.60) 0.001
*P value for linearity across the groups.
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74 DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 care.diabetesjournals.orgto previous population-based studies
(2,4,8), we used the standard diagnostic
procedure with OGTT in deﬁning diabe-
tes and glucose regulation abnormalities.
We conclude that compared with
people with NGR or IGR, people with di-
agnosed type 2 diabetes more commonly
had depressive symptoms. People with
previously unknown diabetes did not dif-
fer from people with NGR or IGR. The
ﬁndings of the present study support the
hypothesis that an increased level of de-
pressive symptoms among people with
type2diabetesisrelatedtotheirexcessive
disease burden, physical activity, and
marital status.
Acknowledgments— FIN-D2D was sup-
ported by ﬁnancing from hospital districts of
Pirkanmaa, southern Ostrobothnia, north Os-
trobothnia, central Finland, and northern
Savo; the Finnish National Public Health In-
stitute; the Finnish Diabetes Association; the
Ministry of Social Affairs and Health in Fin-
land; Finland’s Slottery Machine Association;
the Academy of Finland (grant no. 129293);
the Commission of the European Communi-
ties; the Directorate C-Public Health (grant
agreement no. 2004310) in cooperation with
the FIN-D2D Study Group; and the Steering
Committee(members:J.Huttunen,A.Kesa ¨ni-
emi, S. Kiuru, L. Niskanen, H. Oksa, J. Pihla-
jama ¨ki, J. Puolakka, P. Puska, T. Saaristo, M.
Vanhala, and M. Uusitupa).
No potential conﬂicts of interest relevant to
this article were reported.
P.M.researcheddata,contributedtodiscus-
sion, and wrote the manuscript. K.K. re-
searched data, contributed to discussion, and
reviewed/edited the manuscript. T.S. contrib-
uted to discussion and wrote the manuscript.
H.K. contributed to discussion and reviewed/
edited the manuscript. J.E. contributed to dis-
cussion and reviewed/edited the manuscript.
H.P. researched data, contributed to discus-
sion, and reviewed/edited the manuscript.
M.T. contributed to discussion and reviewed/
edited the manuscript. J.S. contributed to dis-
cussion and reviewed/edited the manuscript.
H.K. researched data, contributed to discus-
sion, and reviewed/edited the manuscript.
M.V. researched data, contributed to discus-
sion, and reviewed/edited the manuscript. All
authors contributed substantially to the con-
ception and design or analysis and interpreta-
tion of data and the drafting of the article or
critical revision for important intellectual
content.
FIN-D2D, the implementation project of
the National Program for the Prevention of
Type 2 Diabetes, was conducted in ﬁve
Finnish hospital districts covering a popula-
tion of 1.5 million during the years 2003–
2008 (Saaristo T, Peltonen M, Keina ¨nen-
Kiukaanniemi S, Vanhala M, Saltevo J,
NiskanenL,OksaH,Korpi-Hyo ¨va ¨ltiE,Tuom-
ilehto J, the FIN-D2D Study Group. National
type 2 diabetes prevention program in Fin-
land: FIN-D2D. Int J Circumpolar Health
2007;66:101–112; Saaristo TE, Barengo NC,
Korpi-Hyo ¨va ¨lti E, Oksa H, Puolijoki H, Salt-
evo JT, Vanhala M, Sundvall J, Saarikoski L,
Peltonen M, Tuomilehto J. High prevalence of
obesity, central obesity and abnormal glucose
tolerance in the middle-aged Finnish popula-
tion. BMC Public Health 2008;8:423). The
main objective was to build up a nationwide
program for the prevention of type 2 diabetes.
FIN-D2D was initiated by the Finnish Diabe-
tes Association with ﬁve Finnish hospital dis-
tricts in collaboration with the national
National Institute for Health and Welfare and
the Ministry of Social Affairs and Health in
cooperation with the FIN-D2D Study Group.
Thespeciﬁcaimsweretoimprovescreeningof
people at risk for diabetes and detection of
undiagnosed diabetes. Furthermore, intensi-
ﬁed interventions of high-risk individuals
were developed and tested as part of normal
clinical practice in primary health care.
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